[
  {
    "criterion": "Suggests medications not proven to have cardiovascular benefits or may not be suitable for patients with stable heart failure.",
    "axis": "accuracy",
    "point": -7
  },
  {
    "criterion": "Provides a concise summary of the patient's condition, medication plan, and potential concerns.",
    "axis": "communication_quality",
    "point": 6
  },
  {
    "criterion": "Does not mention the potential risks or side effects of medications.",
    "axis": "completeness",
    "point": -5
  },
  {
    "criterion": "Correctly identifies the patient's condition as type 2 diabetes with stable heart failure and a mild foot ulcer.",
    "axis": "accuracy",
    "point": 8
  },
  {
    "criterion": "Does not provide alternative medication options for patients who are not tolerant of SGLT2 inhibitors.",
    "axis": "completeness",
    "point": -4
  },
  {
    "criterion": "Uses natural language and correct interpretation in the response.",
    "axis": "communication_quality",
    "point": 5
  },
  {
    "criterion": "Does not provide information about the importance of monitoring for eGFR levels when using SGLT2 inhibitors.",
    "axis": "completeness",
    "point": -3
  },
  {
    "criterion": "Correctly recommends SGLT2 inhibitors for patients with stable heart failure and type 2 diabetes.",
    "axis": "accuracy",
    "point": 9
  },
  {
    "criterion": "Does not mention the potential benefits of GLP-1 receptor agonists for patients with type 2 diabetes and stable heart failure.",
    "axis": "completeness",
    "point": -2
  },
  {
    "criterion": "Provides a clear and concise explanation of the patient's condition and medication plan.",
    "axis": "communication_quality",
    "point": 7
  },
  {
    "criterion": "Does not provide information about the importance of monitoring for mild fluid retention when using ACE inhibitors.",
    "axis": "completeness",
    "point": -1
  },
  {
    "criterion": "Correctly recommends GLP-1 receptor agonists as an alternative for patients who are not tolerant of SGLT2 inhibitors.",
    "axis": "accuracy",
    "point": 8
  },
  {
    "criterion": "Does not provide information about the importance of monitoring for mild foot ulcers in patients with type 2 diabetes.",
    "axis": "completeness",
    "point": -1
  },
  {
    "criterion": "Provides a clear and concise summary of the patient's condition, medication plan, and potential concerns, and uses natural language and correct interpretation in the response.",
    "axis": "communication_quality",
    "point": 9
  },
  {
    "criterion": "Does not provide information about the importance of monitoring for ejection fraction levels in patients with stable heart failure.",
    "axis": "completeness",
    "point": -2
  },
  {
    "criterion": "Correctly identifies the patient's condition as type 2 diabetes with stable heart failure and recommends a medication plan that aligns with guidelines.",
    "axis": "accuracy",
    "point": 10
  },
  {
    "criterion": "Does not provide information about the potential benefits of SGLT2 inhibitors for patients with type 2 diabetes and stable heart failure.",
    "axis": "completeness",
    "point": -2
  },
  {
    "criterion": "Provides a clear and concise explanation of the patient's condition, medication plan, and potential concerns, and recommends alternative medication options for patients who are not tolerant of SGLT2 inhibitors.",
    "axis": "communication_quality",
    "point": 9
  },
  {
    "criterion": "Does not provide information about the importance of monitoring for mild fluid retention when using GLP-1 receptor agonists.",
    "axis": "completeness",
    "point": -1
  }
]